Molecular Biology, Diagnosis and Management of Endometrial Cancer

Dear Colleagues,

Endometrial cancer (EC) is the second most common malignancy of the female reproductive system. The main aim of this Special Issue is to present recent advances in the molecular biology, diagnosis and management of EC.

In the past, the sporadic classification of EC cases was based on clinical, metabolic, endocrine and pathological features. More recently, genomic data were used for an updated EC classification, reflecting the increased impact of molecular biology in disease progression and patients’ outcome.

It is widely accepted that systematic surgical staging represents the method of primary EC treatment. Pelvic and para-aortic lymphadenectomy remains an essential part of systematic surgical staging and provides meaningful data regarding the necessity of postoperative adjuvant treatment. Sentinel lymph node mapping and dissection epitomizes an equilibrium between systematic lymphadenectomy and the absence of lymphadenectomy in well-selected EC patients of low and intermediate risk. The non-surgical fertility-sparing approach can be offered only in well-defined subgroups of young EC patients with early-stage disease, a strong desire for fertility preservation and detailed counselling.

In conclusion, the early diagnosis and appropriate therapeutic management of EC patients have a direct effect on patients’ quality of life and overall survival. Moreover, the extent of surgical staging and the type of postoperative adjuvant treatment should be thoroughly individualized on the basis of EC type, disease stage, fertility issues and patient’s general performance status.

Potential topics include, but are not limited to:

• Preoperative evaluation
• Molecular biology
• Systematic surgical staging
• Pelvic and paraaortic lymph node dissection
• Sentinel lymph node mapping and dissection
• Systemic therapy
• Radiotherapy
• Fertility preservation
• Molecular targeted therapies

Dr. Georgios Androutsopoulos
Dr. Georgios Michail
Dr. Thomas Vrekoussis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.